Perspective from Payers | Bonnie Henry, MD, MPH, FRCPC

International Hepatitis Cure & Eradication Meeting 2015

Maximizing SVR with current HCV therapy | Alnoor Ramji, MD, FRCP

International Hepatitis Cure & Eradication Meeting 2015

New Treatment in HCV: Is there need for more therapies? | Jordan Feld, MD, MPH

International Hepatitis Cure & Eradication Meeting 2015

New Treatment Strategies for Hepatitis B | Harry Janssen, MD, PhD

International Hepatitis Cure & Eradication Meeting 2015

New tools for testing and monitoring Hepatitis B and C | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)

International Hepatitis Cure & Eradication Meeting 2015

Baby Boomer Screening in the U.S: Delivering on the promise thus far? | John Ward, MD

International Hepatitis Cure & Eradication Meeting 2015

Point-of-care (POC) testing in Hepatitis B and C | Scott Bowden, PhD

International Hepatitis Cure & Eradication Meeting 2015

Session 1 Panel Discussion

International Hepatitis Cure & Eradication Meeting 2015

A hepatitis C Vaccine: How do we prove it works? | Kimberly Page

International Hepatitis Cure & Eradication Meeting 2015

Hepatitis C Vaccines: Are we making progress? | Christopher M. Walker, PhD

International Hepatitis Cure & Eradication Meeting 2015

Russian HIV Clinical Series 2021 | Recap 15 April

Russian HIV Clinical Series 2021

Update on DDI guidelines of the FDA - in vitro | Xinning Yang, PhD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018

Clinical Pharmacology of Integrase Inhibitors | Giovanni Di Perri, MD, PhD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018

Last advances in HIV pharmacogenomics | Andrea Calcagno, MD, DTM&H

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018

How/when will pharmacogenomics translate into improved clinical care? | David Haas, MD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018

Application of Physiologically based pharmacokinetic (PBPK) Modelling to Drug Development Decisions | Joga Gobburu, PhD, MBA

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018

The use of DAA’s in pregnancy in HCV infected mothers | David Burger, PharmD, PhD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018

Viral Dynamics and the Search for an HIV Cure | Stephen Becker, MD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018

Clinical Development of Long-Acting Broadly Neutralizing Monoclonal Antibodies: Lessons Learned Thus Far | Richard Koup, MD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018

How to End the Global HCV Epidemic - the role of injectables | David Thomas, MD, PhD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018

Debate: Can we eliminate HCV from Africa? | Mark Nelson, MD

International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2018

Debate: Can we eliminate HCV from Africa? | Richard Njouom, PhD

International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2018

The new epidemic of drug resistant HIV-1 | Gillian Hunt, PhD

International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2018

ALERRT - The African coaLition for Epidemic Research, Response and Training | Peter Horby, MD, PhD

International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2018